This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Industrial Production Beats Expectations in November
by Zacks Equity Research
Industrial Production Beats Expectations in November.
Sector ETFs to Gain the Most on COVID-19 Vaccine Rollout
by Sweta Killa
The United States has geared up for the largest-ever immunization with the rollout of the COVID-19 vaccine.
Markets Swing Back Up on Vaccine Positivity
by Mark Vickery
Import Prices, Empire State and Industrial Production numbers join new positive data from the FDA on Moderna's (MRNA) vaccine candidate.
Stock Market News for Dec 15, 2020
by Zacks Equity Research
Wall Street closed mixed on Monday as investors remained concerned about recent spike in new COVID-19 cases in the United States and Eurozone.
Gaming ETF (BJK) Hits a New 52-Week High
by Sweta Killa
This gaming ETF hits a new 52-week high. Are more gains in store for this ETF?
CureVac (CVAC) Begins Pivotal Study on COVID-19 Vaccine
by Zacks Equity Research
CureVac (CVAC) doses the first patient in a pivotal study on its COVID-19 vaccine candidate, CVnCoV. Shares rise following this development.
US Starts COVID-19 Vaccine Drive: 5 Consumer Discretionary Picks
by Ritujay Ghosh
The COVID-19 vaccine comes as a relief, indicating that the economy might bounce back in the coming days helping stocks like WilliamsSonoma (WSM), Reynolds Consumer Products (REYN) and Spectrum Brands Holdings (SPB).
Vaccines Get to America, but Congressional Relief Lacking
by Mark Vickery
Market indexes began the day solidly in the green, but a bit of bearish trepidation crept in during the day, helping the Dow and S&P 500 finish down.
Key Reasons Why UPS Stock Should Grace Your Portfolio Now
by Zacks Equity Research
The surge in e-commerce growth in the current scenario is a huge boon for UPS.
Wall Street Surges on COVID-19 Vaccine Approval
by Zacks Equity Research
Wall Street Surges on COVID-19 Vaccine Approval.
Historic Day for Pfizer (PFE), Covid-19 Vaccine
by Mark Vickery
With more than 180K daily reported cases as of yesterday, with more than 109K hospitalizations and nearly 1500 deaths on Sunday alone, this vaccine availability is not just historic, it's momentous.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Occidental Petroleum, Devon Energy, Diamondback Energy, Baker Hughes and Marathon Oil
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Occidental Petroleum, Devon Energy, Diamondback Energy, Baker Hughes and Marathon Oil
5 High Earnings Yield Bets Amid an Uncertain Santa Rally
by Rimmi Singhi
Check out these five high earnings yield stocks that can make you rich, irrespective of the Santa rally or a year-end pullback.
COVID-19 Vaccine Race Heats Up as Pfizer Gets Emergency Nod
by Kinjel Shah
FDA grants emergency use approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate.
Producer Price Index in Line With Expectations
by Zacks Equity Research
Producer Price Index in Line With Expectations
Glaxo (GSK)/Sanofi Delay Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
Glaxo (GSK)/Sanofi's (SNY) adjuvanted recombinant COVID-19 vaccine candidate shows low immune response in older adults in phase I/II study. The companies will develop the vaccine with an improved antigen formulation.
Government Shutdown Looms, Vaccine Nears Passage
by Mark Vickery
If the government shuts down, talks cease on pandemic relief allotments, including Pandemic Unemployment Assistance (PUA), which is due to expire the day after Christmas.
Pfizer/BioNTech COVID-19 Vaccine Gets FDA Panel's Backing
by Zacks Equity Research
An FDA panel recommends granting approval for emergency use of Pfizer's (PFE)/BioNTech's (BNTX) COVID-19 vaccine
Moderna (MRNA) Starts COVID-19 Vaccine Study in Adolescents
by Zacks Equity Research
Moderna (MRNA) initiates development of its coronavirus vaccine candidate, mRNA-1273, in adolescent patients in a phase II/III study.
5 Bank Stocks to Gain Amid Potential Economic Recovery
by Zacks Equity Research
Low mortgage rates, falling provisions, vaccine news and hopes of stimulus aid bode well for banks, making it wise to invest in names like BOK Financial (BOKF) and First Hawaiian (FHB).
Energy Sector Up 21% in Past 3 Months: Will the Rally Last?
by Nilanjan Choudhury
Occidental Petroleum (OXY) is the top performing energy stock within the S&P 500 in the past 3 months with a gain of 108.6% while Devon Energy (DVN) is the next best name on the list, soaring 84.8%.
3 Online Education Stocks to Buy as Coronavirus Fears Rise
by Ritujay Ghosh
The COVID-19 pandemic has completely changed the concept of learning, which has led to the popularity of online education stocks like American Public Education, Inc. (APEI), GP Strategies Corporation (GPX) and Lincoln Educational Services Corporation (LINC).
Pfizer/BioNTech COVID-19 Vaccine Raises New Safety Concerns
by Zacks Equity Research
The Bell's palsy related side-effects are not alarming enough to preclude FDA from granting emergency approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine.
Markets Book Profits as Vaccine Rally Stalls; DASH Jumps 86% on IPO
by Mark Vickery
DoorDash (DASH) shares closed its first day on the New York Stock Exchange at $189 per share.
Roche (RHHBY), Moderna Ink Deal for Coronavirus Antibody Test
by Zacks Equity Research
Roche (RHHBY) partners with Moderna to allow the latter utilize its Elecsys Anti-SARS-CoV-2 S antibody test in the mRNA-1273 vaccine research studies.